Study on establishing a methodology of comprehensive clinical evaluation for Chinese patent medicine based on health technology assessment.
10.19540/j.cnki.cjcmm.20200624.501
- Author:
Xing LIAO
1
;
Wu-Dong GUO
2
;
Zhuang CAO
3
;
Hai-Yu XU
4
;
Yun-Ling ZHANG
5
;
Hui ZHAO
6
;
Yong-Yan WANG
1
Author Information
1. Center for Evidence Based Chinese Medicine,Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences Beijing 100700,China.
2. Division of Appraisal and Transformation,Department of Health Technology Assessment,China National Health Development Research Center,National Health Commission Beijing 100037,China.
3. Institute of National Healthcare Security Administration,Capital Medical University Beijing 100070,China.
4. Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700,China.
5. Xiyuan Hospital,China Academy of Chinese Medical Sciences Beijing 100091,China.
6. China Academy of Chinese Medical Sciences Beijing 100700,China China Center for Evidence Based Traditional Chinese Medicine Beijing 100700,China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
EVIDEM;
drug comprehensive evaluation;
health technology assessment;
multi-criteria decision analysis
- MeSH:
China;
Drugs, Essential;
Medicine, Chinese Traditional;
Nonprescription Drugs;
Technology Assessment, Biomedical
- From:
China Journal of Chinese Materia Medica
2020;45(16):3749-3758
- CountryChina
- Language:Chinese
-
Abstract:
At present, most of Chinese patent medicines have problems, such as weak scientific basis, unclear clinical value evaluation, etc., which lead to the lack of sufficient evidence for the entry into the essential medicine list, medical insurance catalog and other important health resource allocation tools. This has a negative impact on the development of traditional Chinese medicine. It is urgent to establish a comprehensive evaluation methodology system of Chinese patent medicine in China. There are at least three reasons including producing evidence for clinical rational use scientifically, developing an objective and transparent selecting strategy, eventuating and highlighting its clinical value. The process and method of health technology assessment(HTA) can provide reference for the establishment of comprehensive evaluation method of Chinese patent medicine. However, HTA is rarely carried out in the field of traditional Chinese medicine. The latest domestic and international research showed that HTA combined with multi-criteria decision analysis(MCDA) can increase the transparency of decision-making and improve the quality of decision-making. The combined two formed the EVIDEM framework, which is conducive to drug selection and its clinical use. In this paper, the EVIDEM framework was introduced to establish the methodology framework of the comprehensive clinical evaluation system of Chinese patent medicine. A preliminary research idea has been put forward. In the future, we can establish a set of comprehensive clinical evaluation methods for Chinese patent medicine in cooperation with relevant national drug decision-making departments and management departments. It is believed that such cooperation could promote the full implementation of the re-evaluation for Chinese patent medicine.
